GSK’s IBAT inhibitor wins US FDA nod for cholestatic pruritus

AI Briefing

• – GSK's Lynavoy (linerixibat) receives FDA approval for cholestatic pruritus
• – Lynavoy is an ileal bile acid transporter inhibitor for primary biliary cholangitis patients
• – Approval marks first new treatment for cholestatic pruritus in decades